Sayan Mutlay, Vempati Prashant, Miles Brett, Teng Marita, Genden Eric, Demicco Elizabeth G, Misiukiewicz Krzysztof, Posner Marshall, Gupta Vishal, Bakst Richard L
University of Vermont, College of Medicine, Burlington, VT, U.S.A.
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai Hospital, New York, NY, U.S.A.
Anticancer Res. 2016 Aug;36(8):4165-70.
We compared the clinical outcomes and toxicity profile among a retrospective cohort of patients with primary major salivary gland carcinomas (SGCs) treated with surgery followed by adjuvant radiation therapy (S+RT) versus surgery and adjuvant chemoradiotherapy (S+CRT).
Twenty patients (71%) underwent S+RT and eight (29%) S+CRT at our Institution between 2006 and 2015. Microscopic positive margins were present in 54% of the patients.
The 3-year overall survival (OS) was 100% with S+RT and 87.5% with S+CRT (p=0.141) and locoregional control (LRC) was 95% with S+RT and 87.5% with S+CRT (p=0.383). There were no significant differences in the rate of acute (p=0.801) and late (p=0.714) toxicities.
While we await randomized data, adjuvant CRT may be considered as a viable therapeutic option for patients at high-risk of local or regional recurrence, especially in those with a positive microscopic margin where further surgery may result in functional cranial neuropathies.
我们比较了接受手术加辅助放疗（S+RT）与手术加辅助放化疗（S+CRT）治疗的原发性大唾液腺癌（SGC）患者回顾性队列的临床结局和毒性特征。
2006年至2015年间，我院20例患者（71%）接受了S+RT，8例（29%）接受了S+CRT。54%的患者存在显微镜下切缘阳性。
S+RT组3年总生存率（OS）为100%，S+CRT组为87.5%（p=0.141）；局部区域控制率（LRC）S+RT组为95%，S+CRT组为87.5%（p=0.383）。急性毒性（p=0.801）和晚期毒性（p=0.714）发生率无显著差异。
在等待随机数据的同时，辅助放化疗可被视为局部或区域复发高危患者的一种可行治疗选择，尤其是那些显微镜下切缘阳性、进一步手术可能导致功能性颅神经病变的患者。
